Apellis (APLS) R&D chief awarded 45,220 RSUs in latest Form 4

Rhea-AI Filing Summary

Apellis Pharmaceuticals’ Chief Research and Development officer Leslie Meltzer reported a stock-based compensation grant. On January 28, 2026, Meltzer received 45,220 shares of Apellis common stock at a price of $0 per share, reflecting a restricted stock unit award.

Following this grant, Meltzer beneficially owns 107,024 shares directly. The award vests 25% each year over four years from the grant date, and vesting is conditioned on continued service with the company.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MELTZER LESLIE

Role Chief Research and Development

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	45,220	$0.00	--

Holdings After Transaction: Common Stock — 107,024 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MELTZER LESLIE

(Last) (First) (Middle)

C/O APELLIS PHARMACEUTICALS, INC.

100 FIFTH AVENUE, 3RD FLOOR

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research and Development

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		A		45,220(1)	A	$0	107,024	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service.

	/s/ David Watson, attorney-in-fact for Leslie Meltzer	01/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Apellis (APLS) report for Leslie Meltzer?

Apellis reported that Chief Research and Development officer Leslie Meltzer received 45,220 shares of common stock as a stock-based compensation grant. The shares were awarded at a price of $0 per share and increased Meltzer’s direct beneficial ownership to 107,024 shares.

Was the Apellis (APLS) insider transaction a purchase or an award?

The reported transaction was an equity award, not an open-market purchase. Leslie Meltzer received 45,220 shares of common stock at $0 per share as a restricted stock unit grant, representing stock-based compensation rather than a cash-funded share acquisition.

How many Apellis (APLS) shares does Leslie Meltzer own after the Form 4?

After the reported transaction, Leslie Meltzer beneficially owns 107,024 shares of Apellis common stock directly. This total includes the 45,220 shares received on January 28, 2026 as part of a restricted stock unit award subject to multi-year vesting.

What are the vesting terms of Leslie Meltzer’s Apellis (APLS) RSU award?

The restricted stock unit award granted to Leslie Meltzer vests 25% annually over four years from the January 28, 2026 grant date. Vesting is conditioned on continued service with Apellis, meaning unvested portions may be forfeited if service ends earlier.

What is the transaction code used in Leslie Meltzer’s Apellis (APLS) Form 4?

The Form 4 uses transaction code “A”, indicating an acquisition of securities. In this case, it reflects the grant of 45,220 shares of common stock as a restricted stock unit award rather than a market purchase, all held under direct ownership after the grant.